These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37907543)

  • 1. IL-8 is a novel prometastatic chemokine in intrahepatic cholangiocarcinoma that induces CXCR2-PI3K/AKT signaling upon CD97 activation.
    Meng ZW; Zhang L; Cai XR; Wang X; She FF; Chen YL
    Sci Rep; 2023 Oct; 13(1):18711. PubMed ID: 37907543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brusatol suppresses the growth of intrahepatic cholangiocarcinoma by PI3K/Akt pathway.
    Chen Z; He B; Zhao J; Li J; Zhu Y; Li L; Bao W; Zheng J; Yu H; Chen G
    Phytomedicine; 2022 Sep; 104():154323. PubMed ID: 35858516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway.
    Liu LZ; He YZ; Dong PP; Ma LJ; Wang ZC; Liu XY; Duan M; Yang LX; Shi JY; Zhou J; Fan J; Gao Q; Wang XY
    Oncotarget; 2016 Nov; 7(46):75210-75220. PubMed ID: 27655691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
    Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
    Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced expression of suppresser of cytokine signaling 3 inhibits the IL-6-induced epithelial-to-mesenchymal transition and cholangiocarcinoma cell metastasis.
    Zhou QX; Jiang XM; Wang ZD; Li CL; Cui YF
    Med Oncol; 2015 Apr; 32(4):105. PubMed ID: 25744243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. M2-polarized tumor-associated macrophages promote epithelial-mesenchymal transition via activation of the AKT3/PRAS40 signaling pathway in intrahepatic cholangiocarcinoma.
    Sun D; Luo T; Dong P; Zhang N; Chen J; Zhang S; Dong L; Janssen HLA; Zhang S
    J Cell Biochem; 2020 Apr; 121(4):2828-2838. PubMed ID: 31692069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COUP-TFII promotes metastasis and epithelial-to-mesenchymal transition through upregulating Snail in human intrahepatic cholangiocarcinoma.
    Lang Q; Xiao P; Zhao M; Liang D; Meng Q; Pei T
    Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(11):1247-1256. PubMed ID: 33166992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FXR Acts as a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition.
    Lv B; Ma L; Tang W; Huang P; Yang B; Wang L; Chen S; Gao Q; Zhang S; Xia J
    Cell Physiol Biochem; 2018; 48(1):158-172. PubMed ID: 30001540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway.
    Zhu B; Wei Y
    Cancer Med; 2020 Jan; 9(2):783-796. PubMed ID: 31957323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
    Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
    J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β-Eudesmol Inhibits the Migration of Cholangiocarcinoma Cells by Suppressing Epithelial-Mesenchymal Transition via PI3K/AKT and p38MAPK Modulation.
    Acharya B; Chajaroenkul W; Na-Bangchang K
    Asian Pac J Cancer Prev; 2022 Aug; 23(8):2573-2581. PubMed ID: 36037109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MUC1 induces the accumulation of Foxp3
    Zhang G; Zheng G; Zhang H; Qiu L
    Int Immunopharmacol; 2023 May; 118():110091. PubMed ID: 37018979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SQSTM1/p62 in intrahepatic cholangiocarcinoma promotes tumor progression via epithelial-mesenchymal transition and mitochondrial function maintenance.
    Chen J; Gao Z; Li X; Shi Y; Tang Z; Liu W; Zhang X; Huang A; Luo X; Gao Q; Ding G; Song K; Zhou J; Fan J; Fu X; Ding Z
    Cancer Med; 2023 Jan; 12(1):459-471. PubMed ID: 35676831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
    Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
    Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLR2 promotes human intrahepatic cholangiocarcinoma cell migration and invasion by modulating NF-κB pathway-mediated inflammatory responses.
    Liu B; Yan S; Jia Y; Ma J; Wu S; Xu Y; Shang M; Mao A
    FEBS J; 2016 Oct; 283(20):3839-3850. PubMed ID: 27616304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells.
    Deng S; Zhang L; Li J; Jin Y; Wang J
    Tissue Cell; 2022 Jun; 76():101756. PubMed ID: 35217388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications.
    Zhang C; Liu LX; Dong ZR; Shi GM; Cai JB; Zhang PF; Ke AW; Yu JX; Zhou J; Fan J
    Tumour Biol; 2015 Mar; 36(3):1781-9. PubMed ID: 25391422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
    Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
    Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liensinine inhibits progression of intrahepatic cholangiocarcinoma by regulating TGF-β1 /P-smad3 signaling through HIF-1a.
    Zhu X; Bao W; Xie X; Chen B; Li R; Zhao J; Wu L; Yu Z; Li S; Zhu Q; Chen G; Li J
    Mol Carcinog; 2024 Apr; 63(4):772-784. PubMed ID: 38289159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.